Eric P. Lester

2.3k total citations
60 papers, 1.8k citations indexed

About

Eric P. Lester is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Eric P. Lester has authored 60 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 13 papers in Molecular Biology and 12 papers in Surgery. Recurrent topics in Eric P. Lester's work include Lung Cancer Treatments and Mutations (9 papers), Lymphoma Diagnosis and Treatment (9 papers) and Advanced Proteomics Techniques and Applications (7 papers). Eric P. Lester is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Lymphoma Diagnosis and Treatment (9 papers) and Advanced Proteomics Techniques and Applications (7 papers). Eric P. Lester collaborates with scholars based in United States, India and United Kingdom. Eric P. Lester's co-authors include Stanley Yachnin, Herbert L. Cooper, Lewis E. Lipkin, John B. Miller, J.E. Folk, Soo Il Chung, J. Schrode, Everett E. Vokes, Janet Dancey and Koen van Besien and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Eric P. Lester

60 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric P. Lester United States 25 618 450 402 371 286 60 1.8k
Itaru Yamamoto Japan 23 428 0.7× 207 0.5× 355 0.9× 501 1.4× 109 0.4× 88 1.9k
Jaudah Al‐Maghrabi Saudi Arabia 27 851 1.4× 574 1.3× 342 0.9× 355 1.0× 334 1.2× 177 2.2k
Nils Brünner Denmark 29 1.2k 2.0× 1.0k 2.3× 165 0.4× 322 0.9× 194 0.7× 96 2.4k
Moritoshi Kinoshita Japan 28 1.0k 1.6× 538 1.2× 136 0.3× 200 0.5× 183 0.6× 75 2.3k
Lifang Yang China 27 1.4k 2.3× 789 1.8× 208 0.5× 211 0.6× 198 0.7× 82 2.5k
Shaoyu Yan United States 25 910 1.5× 595 1.3× 180 0.4× 421 1.1× 120 0.4× 39 1.9k
François Lokiec France 30 1.8k 3.0× 1.3k 2.8× 178 0.4× 358 1.0× 200 0.7× 143 3.3k
Anne‐Lise Børresen Norway 21 1.1k 1.7× 1.0k 2.3× 363 0.9× 233 0.6× 311 1.1× 56 2.4k
Peter Ellinghaus Germany 28 1.6k 2.7× 444 1.0× 519 1.3× 380 1.0× 114 0.4× 74 3.1k

Countries citing papers authored by Eric P. Lester

Since Specialization
Citations

This map shows the geographic impact of Eric P. Lester's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric P. Lester with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric P. Lester more than expected).

Fields of papers citing papers by Eric P. Lester

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric P. Lester. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric P. Lester. The network helps show where Eric P. Lester may publish in the future.

Co-authorship network of co-authors of Eric P. Lester

This figure shows the co-authorship network connecting the top 25 collaborators of Eric P. Lester. A scholar is included among the top collaborators of Eric P. Lester based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric P. Lester. Eric P. Lester is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Monsma, David J., David Cherba, Sean Vance, et al.. (2014). Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance. Pediatric Blood & Cancer. 61(9). 1570–1577. 16 indexed citations
2.
Cohen, Ezra E.W., Daniel J. Haraf, Rangesh Kunnavakkam, et al.. (2010). Epidermal Growth Factor Receptor Inhibitor Gefitinib Added to Chemoradiotherapy in Locally Advanced Head and Neck Cancer. Journal of Clinical Oncology. 28(20). 3336–3343. 64 indexed citations
3.
Choong, Nicholas W., Ann M. Mauer, Daniel J. Haraf, et al.. (2008). Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(9). 1003–1011. 56 indexed citations
4.
Choong, Nicholas W., Ann M. Mauer, Eric P. Lester, et al.. (2007). C3-01: Phase I Trial of Erlotinib-based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 2(8). S364–S365. 1 indexed citations
5.
Peterson, Amy, Helena Harlin, Theodore Karrison, et al.. (2006). A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma. Investigational New Drugs. 24(2). 141–149. 17 indexed citations
6.
Smith, Sonali M., Barbara Pro, Scott E. Smith, et al.. (2006). Molecular Inhibition of mTOR with Temsirolimus (TORISEL™, CCI-779) Is a Promising Strategy in Relapsed NHL: The University of Chicago Phase II Consortium.. Blood. 108(11). 2483–2483. 6 indexed citations
7.
Lester, Eric P., Gina R. Petroni, Maurice Barcos, et al.. (2001). Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Etoposide (CHOPE) for Advanced-Stage Hodgkin's Disease: CALGB 8856. Cancer Investigation. 19(5). 447–458. 5 indexed citations
8.
Hesketh, Paul J., Thomas Beck, Mary Uhlenhopp, et al.. (1995). Adjusting the dose of intravenous ondansetron plus dexamethasone to the emetogenic potential of the chemotherapy regimen.. Journal of Clinical Oncology. 13(8). 2117–2122. 24 indexed citations
9.
Grunberg, Steven M., Montague Lane, Eric P. Lester, et al.. (1993). Randomized double-blind comparison of three dose levels of intravenous ondansetron in the prevention of cisplatin-induced emesis. Cancer Chemotherapy and Pharmacology. 32(4). 268–272. 14 indexed citations
10.
Beck, Thomas, Paul J. Hesketh, Stefan Madajewicz, et al.. (1992). Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.. Journal of Clinical Oncology. 10(12). 1969–1975. 77 indexed citations
11.
Vokes, Everett E., Rosemarie Mick, Eric P. Lester, W. R. Panje, & Ralph R. Weichselbaum. (1991). Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution.. Journal of Clinical Oncology. 9(8). 1376–1384. 35 indexed citations
12.
Fontanesi, James, et al.. (1991). Concomitant cisplatin and hyperfractionated external beam irradiation for advanced malignancy of the head and neck. The American Journal of Surgery. 162(4). 393–396. 8 indexed citations
13.
14.
Hesketh, Paul J., William K. Murphy, Eric P. Lester, et al.. (1989). GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.. Journal of Clinical Oncology. 7(6). 700–705. 80 indexed citations
15.
Dowlatshahi, Kambiz, Eric P. Lester, Marluce Bibbo, & Charles F. Johnson. (1985). Brush cytology for the early detection of esophageal carcinoma among patients with upper aerodigestive malignancies. The Laryngoscope. 95(8). 971–975. 3 indexed citations
16.
Lester, Eric P., Peter F. Lemkin, & Lewis E. Lipkin. (1984). Protein Indexing in Leukemias and Lymphomas. Annals of the New York Academy of Sciences. 428(1). 158–172. 9 indexed citations
17.
Lester, Eric P., et al.. (1980). Computer-assisted analysis of two-dimensional electrophoreses of human lymphoid cells.. Clinical Chemistry. 26(10). 1392–1402. 31 indexed citations
18.
Lester, Eric P., et al.. (1979). Necrotizing Myelopathy Complicating Hodgkin's Disease. Archives of Neurology. 36(9). 583–585. 25 indexed citations
19.
Mintz, Uri, John B. Miller, Harvey M. Golomb, et al.. (1979). Pathologic stage I and II Hodgkin's disease, 1968-1975. Relapses and results of retreatment. Cancer. 44(1). 72–79. 14 indexed citations
20.
Lester, Eric P., John B. Miller, & Stanley Yachnin. (1977). A postsynthetic modification of human α-fetoprotein controls its immunosuppressive potency. Proceedings of the National Academy of Sciences. 74(9). 3988–3992. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Itaru Yamamoto Breakdown of academic impact, for papers by Jaudah Al‐Maghrabi Breakdown of academic impact, for papers by Nils Brünner Breakdown of academic impact, for papers by Moritoshi Kinoshita Breakdown of academic impact, for papers by Lifang Yang Breakdown of academic impact, for papers by Shaoyu Yan Breakdown of academic impact, for papers by François Lokiec Breakdown of academic impact, for papers by Anne‐Lise Børresen Breakdown of academic impact, for papers by Peter Ellinghaus
Rankless by CCL
2026